New drug approved for chemotherapy nausea

August 18, 2016

FDA recently approved granisetron (Sustol, Heron Therapeutics) extended-release injection to prevent nausea and vomiting associated with repeat courses of chemotherapy.

FDA recently approved granisetron (Sustol, Heron Therapeutics) extended-release injection to prevent nausea and vomiting associated with repeat courses of chemotherapy.

Sustol is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

Related: First chemotherapy antidote available soon

The extended-release injectable utilizes Heron’s Biochronomer polymer-based drug delivery technology to maintain therapeutic levels of granisetron for 5 days, covering both the acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV).

“Despite advances in the management of CINV, up to half of patients receiving chemotherapy can still experience CINV, with delayed CINV being particularly challenging to control,” said Ralph V. Boccia, MD, medical director, of the Center for Cancer and Blood Disorders. “In our experience, other 5-HT3 receptor antagonists, including palonosetron, are generally effective for 48 hours or less. Sustol, due to its extended-release profile, represents a novel option that can protect patients from CINV for a full 5 days.”

Related: FDA approves Varubi for chemotherapy-induced nausea

Sustol’s global phase 3 development program was comprised of two, large, guideline-based clinical trials that evaluated its efficacy and safety in more than 2,000 patients with cancer. Sustol’s efficacy in preventing nausea and vomiting was evaluated in both the acute phase (day 1 following chemotherapy) and the delayed phase (days 2 through 5 following chemotherapy).

"The Sustol clinical trial populations and results are highly representative of cancer patients in our real-world clinical practice,” said Jeffrey Vacirca, MD, CEO and director of clinical research at North Shore Hematology Oncology Associates and vice president, Community Oncology Alliance. “The most significant challenge for my breast cancer patients receiving AC is chemotherapy-induced nausea and vomiting. Sustol represents a better option to manage this devastating side effect of therapy.”

Read more: Leukemia drug gets US okay, struggles in UK